These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 30877108)

  • 41. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
    Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
    Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
    Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TAM Receptor Inhibition-Implications for Cancer and the Immune System.
    Aehnlich P; Powell RM; Peeters MJW; Rahbech A; Thor Straten P
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801886
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment.
    Umezu D; Okada N; Sakoda Y; Adachi K; Ojima T; Yamaue H; Eto M; Tamada K
    Cancer Immunol Immunother; 2019 Feb; 68(2):201-211. PubMed ID: 30357491
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models.
    Zhuang Y; Li S; Wang H; Pi J; Xing Y; Li G
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):1909-1920. PubMed ID: 30074066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer.
    Wang C; Xu YH; Xu HZ; Li K; Zhang Q; Shi L; Zhao L; Chen X
    J Nanobiotechnology; 2023 Dec; 21(1):476. PubMed ID: 38082443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Requirement of Gamma-Carboxyglutamic Acid Modification and Phosphatidylserine Binding for the Activation of Tyro3, Axl, and Mertk Receptors by Growth Arrest-Specific 6.
    Geng K; Kumar S; Kimani SG; Kholodovych V; Kasikara C; Mizuno K; Sandiford O; Rameshwar P; Kotenko SV; Birge RB
    Front Immunol; 2017; 8():1521. PubMed ID: 29176978
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.
    Brockwell NK; Owen KL; Zanker D; Spurling A; Rautela J; Duivenvoorden HM; Baschuk N; Caramia F; Loi S; Darcy PK; Lim E; Parker BS
    Cancer Immunol Res; 2017 Oct; 5(10):871-884. PubMed ID: 28848054
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
    Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
    Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
    Chaurasiya S; Yang A; Kang S; Lu J; Kim SI; Park AK; Sivanandam V; Zhang Z; Woo Y; Warner SG; Fong Y
    Oncoimmunology; 2020; 9(1):1729300. PubMed ID: 32158622
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Amlexanox enhances the antitumor effect of anti-PD-1 antibody.
    Takeda K; Yano K; Yamada K; Kihara A
    Biochem Biophys Res Commun; 2021 Jun; 560():1-6. PubMed ID: 33965784
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Radioimmunoimaging and targeting treatment in an immunocompetent murine model of triple-negative breast cancer using radiolabeled anti-programmed death-ligand 1 monoclonal antibody.
    Pang X; Liu M; Wang R; Liao X; Yan P; Zhang C
    J Labelled Comp Radiopharm; 2018 Sep; 61(11):826-836. PubMed ID: 29923634
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Bis-Indole-Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity.
    Karki K; Wright GA; Mohankumar K; Jin UH; Zhang XH; Safe S
    Cancer Res; 2020 Mar; 80(5):1011-1023. PubMed ID: 31911554
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
    Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
    J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
    Karachi A; Yang C; Dastmalchi F; Sayour EJ; Huang J; Azari H; Long Y; Flores C; Mitchell DA; Rahman M
    Neuro Oncol; 2019 Jun; 21(6):730-741. PubMed ID: 30668768
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
    J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment.
    Park M; Kuen DS; Park J; Choi M; Kim Y; Roh EC; Choi YJ; Kim YG; Chung Y; Cho SY; Kang KW
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36693679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice.
    Ueha S; Yokochi S; Ishiwata Y; Ogiwara H; Chand K; Nakajima T; Hachiga K; Shichino S; Terashima Y; Toda E; Shand FH; Kakimi K; Ito S; Matsushima K
    Cancer Immunol Res; 2015 Jun; 3(6):631-40. PubMed ID: 25711759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.